There is strong evidence that the amyloid-beta peptide (Ab) plays a central role in the pathogenesis of Alzheimer's disease (AD). In this context, a detailed quantitative description of the interactions with different Ab species is essential for characterization of physiological and artificial ligands. However, the high aggregation propensity of Ab in concert with its susceptibility to structural changes due to even slight changes in solution conditions has impeded surface plasmon resonance (SPR) studies with homogeneous Ab conformer species. Here, we have adapted the experimental procedures to state-of-the-art techniques and established novel approaches to reliably overcome the aforementioned challenges. We show that the application of density gradient centrifugation (DGC) for sample purification and the use of a single chain variable fragment (scFv) of a monoclonal antibody directed against the amino-terminus of Ab allows reliable SPR measurements and quality control of the immobilized Ab aggregate species at any step throughout the experiment.
Introduction
Alzheimer's disease (AD) is the most common form of neurodegenerative disorders. While several genetic risk factors have been identified to be associated with the onset of AD, the major risk factor of AD is age. In 2010 around 35 million people were affected worldwide. With increasing life expectancy, .65 million cases are predicted by 2030 [1] . One of the hallmarks of AD is the appearance of amyloid aggregates [2] . According to the amyloid cascade hypothesis there is evidence that cellular events leading to cell death in AD are initiated by different amyloid betapeptide (Ab) assembly states [3] . This is supported by the observation of extracellular amyloid-like aggregates -mainly consisting of Ab [4] -in the central nervous system of patients suffering from AD. Formation of Ab is catalyzed by proteolytic cleavage of the amyloid precursor protein (APP) by b-secretase and c-secretase [5] . The role of the oligomeric and fibrillar assembly states in disease progression is still debatable.
Nevertheless, due to the strong evidence that Ab plays a central role in the pathogenesis of AD, substantial efforts aim to develop assays that, on the one hand, either allow the detection and quantification of Ab species in biological matrices as for instance cerebrospinal fluids [6, 7] or brain tissue [8] [9] [10] or, on the other hand, allow the characterization of compounds that target different Ab species and/or interfere with their formation. A critical measure describing such compounds is their binding affinities to distinct Ab species. Thus, reliable assays are urgently needed for quantitative affinity determination between ligands and the various Ab species.
An optimal assay for binding studies with Ab-binding molecules should combine minimal consumption of label-free ligands with maximum yield on kinetic and thermodynamic binding data. The surface plasmon resonance (SPR) technology can meet these requirements. In an SPR experiment, one of the interactants is immobilized (ligand) on a sensor chip surface. With regard to the propensity of Ab to aggregate, its use as the ligand is a clear advantage as stable fixation minimizes the risk of structural rearrangements, oligomerization and aggregation throughout the experiment.
However, several challenges exist with respect to the design of an SPR-assay for Ab: (i) For obtaining robust data it is a prerequisite to use preparation techniques that ensure reliable preparation of homogeneous Ab species that are free from undesired aggregation states. Ab readily forms different oligomeric species that vary in size. Hence, samples are frequently heterogeneous, which prevents satisfactory data evaluation and binding curve fitting even when using multi-compound binding models. (ii) It is essential to find a suitable immobilization technique that is compatible with the buffer where formation of the respective Ab species was performed because this prevents structural rearrangement of the prepared species. Many studies have analyzed the effect of different buffer components, temperature and pH on the formation of different Ab species [11] . Taken together even slight changes in one of the latter physical parameters can cause structural rearrangements and peptide instability. Unfortunately, the majority of immobilization techniques in SPR are based on chemical reactions that require a change of solution conditions. Moreover, immobilization of variable amounts of ligand on the surface in a highly reproducible manner is another critical step as this allows adaption of the Rmax (maximum response obtainable when all available ligand binding places are occupied) to the molecular weight of the interaction partner. Since there is a linear dependence of molecular mass to the detected SPR response, analytes with high molecular weights yield higher response signals than smaller analytes [12] . Excessive amounts of ligand eventually lead to heterogeneity in recorded sensorgrams during binding experiments, hampering data evaluation because of mass transport limitations and rebinding events. Generally, the lower the amount of immobilized ligand that yields a sufficient response during interaction with an analyte the lower the risk of heterogeneity. (iii) In addition to preparation and immobilization, special requirements for the measurement procedure are also present. A standard SPR assay includes regeneration steps between multiple analyte injections. This introduces the risk of critical structural rearrangements in the immobilized Ab aggregates. It would therefore be beneficial to circumvent this step to yield reproducible interaction data. (iv) A reference molecule for quality control purposes of the surface activity during every single step of an experiment would greatly facilitate experimental design. Accordingly, selection of a proper analyte for assay development and surface characterization is crucial. It should be available in sufficient amounts, possess an on-and off-rate within SPR instrument specifications without introducing avidity effects.
Methods

Expression of the single chain variable fragment IC16
For recombinant production of scFv-IC16, E. coli BL21 DE3 pRARE2 was transformed with the expression vector pET22b-scFv-IC16-5His. Each 1 l 2YT (10 g l-1 yeast extract, 20 g l-1 tryptone, 10 g l-1 NaCl, 10 ml l-1 20% dextrose, 5 ml l-1 2 M MgCl 2 , chloramphenicol and ampicillin, pH 7.4) expression culture was inoculated with an aliquot of a 50 ml overnight LB (5 g l-1 yeast extract, 10 g l-1 tryptone, 10 g l-1 NaCl) culture (grown at 37uC, 150 rpm) to a final OD 600 of ,0.1. Cells were grown at 37uC (150 rpm) to an OD 600 of 1.6-1.8. Subsequently, cultures were chilled for 1 hour at 4uC until IPTG was added to a final concentration of 0.2 mM for induction of scFv-IC16 protein expression. Expression was carried out for 24 hours at 18uC under gentle agitation (150 rpm). Cells were harvested by centrifugation (30 min, 4uC, 3750 rpm), pellets washed with PBS (10 mM sodium phosphate buffer pH 7.4, 137 mM NaCl, 2.7 mM KCl) and stored at 220uC until further use.
Purification of scFv-IC16
Pellets were resuspended in 20 ml lysis buffer I (50 mM TrisHCl pH 8.0, 1 mM EDTA, 1 mg/ml lysozyme), supplemented with protease inhibitors (Complete EDTA-free Protease Inhibitor Cocktail Tablets, Roche). For cell lysis 20% Triton X-100 was added to a final concentration of 1%. MgCl 2 was added to a final concentration of 20 mM together with 500 U DNAse I. After an incubation at RT for ,15 minutes the volume was adjusted to 50 ml with lysis buffer II (8.33 mM imidazole, 833 mM NaCl, 16.6 mM CaCl 2 , 1% Triton X-100) followed by centrifugation for 30 min at 20,000 g. Pellets containing scFv-IC16 in inclusion bodies were resuspended in 30 ml binding buffer (50 mM TrisHCl pH 7.8, 500 mM NaCl, 8 M urea) followed by overnight incubation at 4uC in an orbital shaker. Suspensions were centrifuged (45 min, 20,000 g) and supernatants containing scFv-IC16 were purified by denaturing Ni 
Preparation of Ab(1-42) monomers and oligomers by size exclusion chromatography (SEC)
The protocol used by Johansson, Berglind-Dehlin, Karlsson, Edwards, Gellerfors and Lannfelt [13] was adapted for Ab(1-42) monomer and oligomer preparation by SEC with minor modifications. Lyophilized stocks of Ab(1-42) (Bachem), carboxy-terminally biotinylated Ab(1-42) (Eurogentec) and aminoterminally biotinylated Ab(1-42) (Anaspec) were separately dissolved in 100% hexafluoroisopropanol (HFIP) and incubated overnight at RT. In the case of oligomer preparations, aminoterminally biotinylated Ab(1-42) and non-biotinylated Ab(1-42) were mixed in a 1:10 ratio. After incubation, solutions were divided into 125 mg aliquots. HFIP was removed by evaporation in a Concentrator 5301 (Eppendorf). Ab(1-42) was resolubilized in 100 ml SEC-buffer (50 mM sodium phosphate buffer, 150 mM NaCl, 0.6% Tween 20, pH 7.4) and briefly centrifuged (30 s) at 15,000 g to sediment insoluble material immediately prior to separation by SEC. Separation was performed with a Superdex 75 10/300 GL column operated at RT by an Ä kta purifier system at a flow rate of 0.8 ml min 21 . For each single run ,100 ml of solubilized Ab(1-42) was loaded onto the column. Monomers eluted at ,14 ml, whereas oligomers eluted close to the void volume (at ,8 ml). Samples were immediately used for immobilization on sensor chip surfaces. Initially, for establishment of the immobilization assay a BCA-assay was used to correlate the absorbance at 214 nm of the SEC fractions to the overall Ab concentration. We observed, that an A 214 = 250 mAU (oligomers) or A 214 = 150 mAU (monomers) in the size exclusion chromatogram correlates with ,1 mM total Ab concentration derived from a BCA-assay. Omitting the BCA-assay step dramatically reduces the time between elution and immobilization. For immobilization of monomers and oligomers (10% amino-terminally biotinylated) Ab(1-42) concentrations of ,10 nM and ,100 nM, respectively, were used.
Preparation of Ab(1-42) fibrils
The protocols used by Wood, Maleeff, Hart and Wetzel [14] and Nagel-Steger, Demeler, Meyer-Zaika, Hochdorffer, Schrader and Willbold [15] were adapted for Ab(1-42) fibril preparation with minor modifications. Lyophilized aliquots of Ab(1-42) and amino-terminally biotinylated Ab(1-42) were dissolved separately in 100% HFIP and incubated at RT overnight. Biotinylated Ab(1-42) and non-biotinylated Ab(1-42) in HFIP were mixed in a 1:10 ratio and subsequently divided into 72 mg aliquots. HFIP was removed by evaporation in a Concentrator 5301 (Eppendorf). Then, Ab pellets were solubilized in 200 ml sodium phosphate buffer pH 7.4 (10 mM; yielding an 80 mM Ab solution) and incubated for 24 hours at 25uC (600 rpm). To separate the hereby obtained fibrils from smaller aggregates and from monomers, they were subjected to a density gradient centrifugation (DGC) step. The gradient was prepared in thin-walled ultracentrifugation tubes (Ultra-Clear 11634 mm, 2.2 ml from Beckman) by successively overlaying the following volumes of density gradient solutions: 260 ml 50%, 260 ml 40%, 260 ml 30%, 780 ml 20%, 260 ml 10% and 100 ml 5% (v/v) Iodixanol in 10 mM sodium phosphate buffer pH 7.4. After addition of 100 ml sample, the gradient was centrifuged (3 h, 4uC, 259,000 g) using a TLS-55 rotor in a benchtop ultracentrifuge Optima TL-100 (Beckman-Coulter). From each gradient 14 fractions of 140 ml were harvested from top to bottom. Fibrils were typically located in fractions 11 to 13.
Surface Plasmon Resonance (SPR)
For SPR experiments Series S Sensor Chips SA (GE Healthcare Life Sciences) in combination with a Biacore T200 system were used. Series S Sensor Chips SA are coated with streptavidin and allow ligand immobilization based on the biotin-streptavidin interaction. For our experiments PBS (filtered with 0.2 mm, PVDF) was used as running buffer. After docking a new sensor chip, the system was initiated with a ''Prime'' command and the detector normalized with 70% glycerol (GE Healthcare Life Sciences). All flow cells were activated with three consecutive one minute injections of 1 M NaCl in 50 mM NaOH. For ligand immobilization the flow rate was adjusted to 5 ml min 21 in order to minimize sample consumption. After immobilization we let the flow cells stabilize overnight to remove unspecifically bound material and detergence. To do so, we set the flow speed and temperature to 30 ml min 21 and 25uC respectively. For interaction studies the flow speed and temperature were adjusted to 30 ml min 21 and 25uC respectively. All interaction studies were performed in the single-cycle kinetic mode [16] . Here, five different analyte concentrations were injected within a single cycle (contact time: 90 s, final dissociation time after the highest concentration: 1800 s) in order of increasing concentration. The applied analyte concentrations for scFv-IC16 were 312.5, 625, 1250, 2500 and 5000 nM. Binding studies with monoclonal antibody 6E10 were performed with concentrations of 0.32, 1. Double referenced SPR data were evaluated with Biacore T200 Evaluation Software (version 1.0) using the available binding models. Ab monomer data was fit to a 1:1 binding model, whereas sensorgrams of Ab oligomers and fibrils were analyzed with a heterogeneous ligand binding model accounting for two separate ligand sites for analyte binding. Values for bulk refractive index (R I ) and mass transfer (k t ) correction were manually set to zero, because double-referencing was applied and low amounts of ligand were immobilized.
Results
For immobilization of different Ab(1-42) species we have chosen a streptavidin-biotin-coupling procedure as this avoids change in buffer conditions during Ab(1-42) immobilization [17] concomitant with many alternative protocols. In addition, due to the strong interaction of streptavidin and biotin with a dissociation constant K D of around 10 215 M [18] there is virtually no loss of ligand during the experiment. Moreover, streptavidin-biotincoupling can be used effectively to control the amount of bound ligand simply by varying the concentration of the ligand or the duration of the injection. Fig. 1 shows the experimental setup scheme for the preparation of different Ab(1-42) species and their immobilization.
Because any harsh regeneration steps between measurements will very likely do harm to the immobilized Ab(1-42) species, they need to be avoided completely. Instead, very long washing steps have been introduced between separate measurements. To save time, so called kinetic titration [13] , where the analyte is injected in increasing concentrations without regeneration steps inbetween, is the method of choice. In comparison with classical multi-cycle kinetics, sample consumption and analysis time is reduced and, most importantly, the need for regeneration is eliminated [16, 19] . For analysis of the kinetic titration obtained sensorgrams the tool ''single-cycle kinetics'' of the Biacore evaluation software package has been used.
For assay development and for quality check of surface characterization of immobilized Ab species, the single-chain variable fragment (scFv-IC16) of the antibody IC16 that was initially selected to target the first 16 amino-acid residues of Ab was selected [20, 21] . scFvs are easy to produce and purify, stable at high concentrations for at least weeks, and possess only a single binding site with high specificity for their epitope, thereby avoiding any avidity effects.
Characterization of Ab monomers
To test the specificity of scFv-IC16 to the amino-terminal part of Ab, the chosen biotin-streptavidin immobilization procedure should be well-suited. The orientation of Ab on the surface can be modulated easily by changing the location of the biotin tag. In theory it should therefore be possible to hide the epitope of scFv-IC16 by fusion of a biotin tag in close proximity. To do so we have immobilized the amino-terminally biotinylated Ab(1-42) monomers (Fig. S1 A) that have been purified by size exclusion chromatography (SEC) prior to immobilization (Fig. S2 A) [13] . SEC purification ensures monodispersity of Ab monomers. Binding of an anti-Ab(1-42) antibody (6E10) demonstrated that Ab was successfully immobilized (Fig. S3) . In contrast, binding of scFv-IC16 to the N-terminally biotinylated Ab(1-42) monomer loaded surface could not be detected (for details see Fig. S4 ). Conversely, C-terminally biotinylated Ab(1-42) monomers that were immobilized to the surface was bound by both, 6E10 and scFv-IC16 (Fig. 2 and Fig. S5 ). We conclude that both, N-and Cterminally biotinylated Ab monomers were successfully immobilized, but immobilization of N-terminally biotinylated Ab(1-42) on the streptavidin-coated sensor chip restricts binding of scFv-IC16. To extract quantitative information from the experimental data of scFv-IC16 and C-terminally biotinylated Ab(1-42) we fitted the obtained sensorgrams to a Langmuir 1:1 binding model. Refractive index correction (R I ) was not required because all binding data were double referenced prior to analysis. As can be seen in Fig. 2 
Characterization of an example for Ab oligomers
Next we immobilized Ab(1-42) oligomers containing 10% amino-terminally biotinylated Ab(1-42) and checked for successful immobilization of Ab with 6E10 and scFv-IC16. To reduce the risk of sample heterogeneity we removed species different than oligomers by SEC [13] and immediately immobilized these oligomers (Fig. S1 A) . 6E10 and scFv-IC16 were both able to bind to the Ab oligomers on the surface (see Fig. 2 and Fig. S6) . Importantly, since amino-terminally biotinylated monomers are not recognized by scFv-IC16 we can conclude that the obtained responses rely on scFv-IC16 binding to oligomers. Therefore, scFv-IC16 proves to be a powerful tool for surface characterization and quality control of immobilized Ab and application as a molecular tool for SPR studies with Ab in higher aggregation states is conceivable. Antibodies and their respective Fab fragments are often known to recognize both, linear and conformational epitopes. Binding curves were therefore fit with a heterogeneous ligand binding model. Again, owing to double referencing, a refractive index (RI) correction was not required. We obtained two separate K D values (0.37 mM and 5.60 mM; x 2 : 3.0) with affinities differing by one order of magnitude. Use of simpler models increased x 2 by at least a factor of ten and supports the initial assumption of a second epitope of Ab(1-42) oligomers for scFv-IC16. This effect is very likely not being caused by rebinding effects of the analyte. The total mass of immobilized Ab(1-42) oligomers is very comparable with the amount of immobilized Ab(1-42) monomers, in which clearly no rebinding could be observed (Fig. S1 A) .
Characterization of Ab fibrils
For immobilization of fibrils, an Ab(1-42) mixture with 10% amino-terminally biotinylated Ab(1-42) was used. To ensure the absence of lower molecular weight species we applied density gradient centrifugation (DGC) for separation of fibrils from other oligomeric states and monomers. Iodixanol was used as gradient media because this reagent has several advantages over other potential agents: it is non-ionic, forms self-generated gradients in comparatively short centrifugation times and, most importantly, it is iso-osmotic [22] . This ensures a low influence on protein stability and structure. Nevertheless, to analyze the potential influence of Iodixanol on the structural assembly of the prepared fibrils AFM studies were performed (Fig. S8) . The obtained AFM results indicate that fibril formation is not altered by Iodixanol, that the fibrils are virtually identical to Ab fibrils previously studied by AFM [23] and that no background signal by lower molecular weight species such as oligomers can be observed. As observed for SEC-purified Ab-oligomers, it was possible to immobilize reproducible amounts of the DGC separated Ab-fibrils on the surface (Fig. S1 B) . To the best of our knowledge, this is the first report on the immobilization of Iodixanol DGC-separated Ab(1-42) fibrils via a biotin-streptavidin technique and acts as a proof-of-principle experiment that demonstrates this combination of methods as a powerful tool for future sample preparation of ligands for SPR studies. However, the refractive index shows a dramatic jump following sample injection because of the presence of Iodixanol (Fig. S1 B) . Incubation of the flow cell in a continuous flow mode revealed a linear decay of 4 RU (RU: response units) per hour after 8 h. We assumed this decay is caused by a small amount of the fibrils dissociating, because similar decays have been observed previously for immobilized fibrils [24] . scFv-IC16 was able to bind to the fibril surface. The binding curves were fit with the identical model used for Ab(1-42) oligomers. The resulting dissociation constants for scFv-IC16 binding to Ab(1-42) fibrils were determined to be 0.31 mM and 4.26 mM (x 2 : 1.2, Tab. 1), which are very similar to those obtained for Ab oligomers.
Discussion
A direct comparison of the obtained kinetic rates and overall affinities for scFv-IC16 and Ab species reveals that for each Ab assembly state (C-terminally biotinylated monomers, as well as 10% N-terminally biotinylated oligomers and fibrils), there is one interaction component present with nearly identical properties among all three assembly states (Fig. 3. and , respectively. Based on these rate constants, it is tempting to speculate that the same binding epitope for scFv-IC16 is present in each of the studied Ab assembly states. Because this epitope is obviously missing in purely N-terminally biotinylated monomers, we can conclude that this epitope contains the very N-terminal residues of Ab. Moreover, the affinity of the slower binding reaction of scFv-IC16 binding oligomers and fibrils was nearly one order of magnitude weaker (K D2 -values in Tab. 1). Based on this observation we conclude that Ab generates a secondary binding site for scFv-IC16 when forming higher assembly states like oligomer and fibril structures. Remarkably, fitting of sensorgram data obtained with scFv-IC16 binding monomeric Ab to the heterogeneous ligand binding model, as used for oligomers and fibrils, did not yield a second binding component similar to the oligomer and fibril data. Instead, an unlikely apparent K D of 9.9610 214 M in concert with an R max value of 1.6 supports the notion that scFv-IC16 binding data for monomers follows a 1:1 Langmuir interaction, which confirms that the Ab monomer preparation was extremely homogeneous, and that the secondary binding epitope existing in oligomers and fibrils is clearly not a fitting artefact.
In addition to the specific findings concerning the properties of scFv-IC16, we hereby describe a general approach to immobilize any Ab assembly that contains a fraction of n-terminally biotinylated Ab molecules to streptavidin-coated SPR chips while having the possibility to confirm integrity of the immobilized Ab species via binding of scFv-IC16 at any time of the experiment. IC16 was chosen, because it recognizes the amino-terminus of Ab only, when it is not biotinylated and bound to streptavidin. The scFv fragment of IC16 has been chosen because it binds in a 1:1 ratio to the target and is eluting more rapidly than the full-length IC16 antibody. The setup allows immobilization of either C- terminally Ab monomers or any kind of higher order Ab forms that were artificially prepared employing a fraction of Nterminally biotinylated Ab. We have given one example each of a monomer, oligomer and fibril preparation, as were published previously by others.
Conclusions
Taken together, we have established a novel approach allowing reproducible interaction studies with different homogeneous Ab(1-42) assembly states by SPR. SEC and DGC purification of Ab species prior to streptavidin-biotin coupling ensures sample homogeneity and minimal surface alterations, which are major limitations of SPR experiments involving Ab. In addition, we have employed a monoclonal antibody-derived scFv for direct verification of successfully immobilized higher Ab assembly states. Although, the hereby described approach is straightforward only for in vitro-generated Ab assemblies, it may prove to be an essential step toward future screening and in-depth characterization of potential drug candidates and thereby has the capability to greatly simplify and accelerate drug development for AD. 
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